A genome test—which would have cost over a billion dollars two decades ago—will soon cost less than $100. Advances in genome testing, it is postulated, may make it possible to create personalized drug formulations.
The incidence of prostate cancer amongst South Asians in the US is just 4.6 per 100,000 population as compared to 104.3 per 100,000 amongst non-South Asians. Yet when they come in for treatment, 85 percent of them are usually in the late stages, as compared to late stage prostate cancer diagnosis for non-South Asians which is around 15 percent.
Given the sheer numbers of the South Asian population around the world, it is imperative they get checked early. Dr. Ashutosh K. Tewari, an expert on prostate cancer and robotics, discusses the hard facts.
View Lavina Melwani's profile